The Cloudbreak platform is a fundamentally new approach to the fight against life-threatening infectious disease that provides potent antimicrobial activity and immune system engagement in a single molecule.
Cloudbreak
Anti-infective Immunotherapy Platform
Cloudbreak
Anti-infective Immunotherapy Platform
The Cloudbreak platform is a fundamentally new approach to the fight against life-threatening infectious disease that provides potent antimicrobial activity and immune system engagement in a single molecule.
Cloudbreak Platform Overview
The Cloudbreak platform recognizes that most infectious disease results when a microbial pathogen is able to evade or overcome the host immune system. Our Cloudbreak candidates are designed to counter infection in two ways, by directly targeting and destroying invading pathogens and by focusing the immune system at the site of infection. In this way, Cloudbreak anti-infective candidates are similar to certain cancer immunotherapies that unlock the potential of the immune system to destroy cancer cells.
Multimodal Mechanism of Action from a Single Molecule
Cloudbreak candidates targeting viral infections are called Antiviral Fc-Conjugates (AVCs), single molecules consisting of two distinct moieties with discrete, yet complementary mechanisms of action:
- Targeting Moiety (TM): Novel and highly potent small molecule that binds surface targets on the pathogen to directly destroy it and/or inhibit replication.
- Effector Moiety (EM): Fragment crystallizable (Fc) region of human IgG1 antibodies, which was selected to maximize engagement of the human immune system via Fc-gamma (Fcγ) receptors and for its long half-life.
AVCs not only mediate pathogen clearance through a multimodal mechanism of action but also have potential for months of activity with a single dose.
